|
|
 |
|
|
Kenta's MabIgX® technology for the generation and selection of an advanced class of fully human monoclonal antibodies (MAbs) combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line.
Kenta Biotech Ltd.
Rehhagstrasse 79
CH - 3018 Berne |
Tel: +41 (0) 31 980 6338
Fax: +41 (0) 31 980 6556
info@kentabiotech.com |
|
|
|
